How to Get Evenity (Romosozumab) in Missouri

What Is Romosozumab and Why Does It Matter for Missouri Patients?

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, romosozumab simultaneously increases bone formation and decreases bone resorption, a dual mechanism unique among osteoporosis therapies [1]. The FDA approved Evenity in April 2019 for postmenopausal women with osteoporosis at high risk for fracture [2].

Missouri ranks among states with higher osteoporosis prevalence due to its aging population demographics. According to CDC data, approximately 12.6% of adults aged 50 and older in the United States have osteoporosis at the femoral neck or lumbar spine [3]. For Missouri residents with severe disease who have failed or cannot tolerate bisphosphonates, romosozumab offers a time-limited anabolic treatment window. The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced new vertebral fracture risk by 48% compared with alendronate alone at 24 months [4]. That result changed how endocrinologists sequence therapy for high-risk patients.

The drug carries an FDA boxed warning for potential cardiovascular risk. Romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year [2]. This warning shapes prescribing decisions and prior authorization criteria across Missouri insurers.

Who Can Prescribe Evenity in Missouri?

Any Missouri-licensed prescriber with appropriate scope of practice can write a romosozumab prescription. That includes physicians (MD and DO), nurse practitioners, and physician assistants. NPs in Missouri gained full practice authority in 2023 under Senate Bill 100, meaning they can prescribe Evenity independently without a collaborative physician agreement [5].

Most prescriptions originate from endocrinologists, rheumatologists, or orthopedic specialists. Primary care providers can also prescribe, though many prefer to defer to specialists for anabolic bone agents given the cardiovascular monitoring requirements. The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend romosozumab as first-line therapy for patients at "very high" fracture risk, defined as a recent osteoporotic fracture, a T-score of <-3.0, or a high FRAX probability [6].

A practical consideration: the prescriber's office should be equipped to administer subcutaneous injections, since Evenity is not self-administered at home. Each dose requires two separate 105 mg injections given consecutively at the same visit. Patients visit their provider's office or an infusion center monthly for 12 months.

Telehealth Options for Missouri Residents

Missouri law permits telehealth prescribing for Evenity. The initial consultation, including medical history review, fracture risk assessment, and lab ordering, can occur via video visit. This is particularly relevant for patients in rural Missouri counties where endocrinology access is limited. A 2023 analysis found that 77 of Missouri's 114 counties have zero practicing endocrinologists [7].

The telehealth visit covers the diagnostic and prescribing steps. The prescriber reviews DXA scan results, evaluates FRAX scores, checks cardiovascular history, and orders baseline labs. Once the prescription is written, the patient still needs in-person visits for the monthly injections. Some patients pair a telehealth prescriber with a local clinic or infusion center for administration.

HealthRX connects Missouri patients with board-certified physicians who can evaluate candidacy for romosozumab via telehealth, order required labs, and coordinate with specialty pharmacies for medication delivery. The prescription is then sent to a specialty pharmacy that ships the medication directly to the administering clinic.

Required Labs Before Starting Evenity in Missouri

Before prescribing romosozumab, clinicians in Missouri follow the same evidence-based workup used nationally. Baseline laboratory evaluation serves two purposes: confirming the osteoporosis diagnosis and ruling out contraindications.

Standard pre-treatment labs include serum calcium (corrected for albumin), 25-hydroxyvitamin D, comprehensive metabolic panel, and CBC. Vitamin D levels should be at or above 30 ng/mL before initiating therapy, as hypocalcemia is a known risk with romosozumab [2]. A 2020 post-marketing analysis reported hypocalcemia in 0.4% of patients receiving romosozumab, with higher rates in patients with pre-existing vitamin D deficiency [8].

Additional labs may include serum phosphorus, magnesium, parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), and bone turnover markers such as P1NP (procollagen type I N-terminal propeptide) and CTX (C-terminal telopeptide). These markers help the prescriber track treatment response. P1NP typically rises sharply within the first month of romosozumab therapy, peaking at month 6 before declining [1].

A DXA scan is required to document a T-score consistent with osteoporosis (T-score ≤ -2.5) or severe osteopenia with fracture history. Most Missouri insurers require a DXA performed within the prior 24 months for prior authorization approval.

Cardiac screening is also necessary. Given the boxed warning, prescribers should assess cardiovascular risk factors and obtain a recent lipid panel and blood pressure reading. Patients with a history of MI or stroke within the past 12 months are not candidates [2].

Insurance Coverage and Prior Authorization in Missouri

Prior authorization is the single biggest hurdle for Missouri patients seeking Evenity. The process differs by payer.

Commercial insurance. Most major plans in Missouri (including Blue Cross Blue Shield of Kansas City, Anthem, and UnitedHealthcare) cover Evenity under the medical benefit (not pharmacy benefit) because it is a provider-administered injectable. Prior authorization requirements typically include: a confirmed DXA T-score of ≤ -2.5, documented failure of or intolerance to at least one bisphosphonate, a FRAX 10-year major osteoporotic fracture probability exceeding 20%, and documentation that the patient has no recent cardiovascular events [9].

Missouri Medicaid (MO HealthNet). As of 2026, Missouri Medicaid does not cover Evenity for osteoporosis. The MO HealthNet formulary lists romosozumab only under type 2 diabetes indications, which is a formulary classification error that has persisted despite the drug's approved indication being osteoporosis [10]. Medicaid patients in Missouri should work with their prescriber to file an exception request or pursue the Amgen Assist 360 patient support program.

Medicare Part B. Because Evenity is administered in a clinical setting, it falls under Medicare Part B. Coverage requires a confirmed osteoporosis diagnosis and prior authorization through the Medicare Administrative Contractor (MAC) for the region. The Endocrine Society's 2020 clinical practice guideline supports romosozumab for postmenopausal women at very high fracture risk, and citing this guideline in the authorization letter can strengthen approvals [11].

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has noted: "The prior authorization burden for anabolic bone therapies remains one of the most significant barriers to appropriate treatment. Patients who meet guideline criteria for very high fracture risk are precisely the population that cannot afford treatment delays" [12].

Documentation checklist for prior authorization:

• DXA scan report with T-scores
• FRAX calculation printout
• Clinical notes documenting bisphosphonate trial or contraindication
• Cardiovascular risk assessment and clearance
• Prescriber letter of medical necessity
• Relevant imaging (spine X-rays or VFA showing vertebral fractures)

Turnaround for prior authorization in Missouri averages 5 to 15 business days, though peer-to-peer review requests from insurers can extend the timeline.

Specialty Pharmacy and Medication Access in Missouri

Evenity requires specialty pharmacy dispensing. The medication must be stored at 2°C to 8°C (36°F to 46°F) and shipped via cold chain. Standard retail pharmacies do not stock it.

Major specialty pharmacies serving Missouri patients include Accredo (Express Scripts), Optum Specialty Pharmacy, CVS Specialty, and Biologics by McKesson. The prescriber's office typically coordinates with the patient's insurance-preferred specialty pharmacy. Once prior authorization is approved and the pharmacy receives the prescription, the medication is shipped to the administering clinic (not the patient's home).

Each monthly shipment contains two prefilled syringes of 105 mg/1.17 mL each. The clinic stores the medication under refrigeration until the patient's appointment.

503A compounding pharmacies. Missouri does have licensed 503A compounding pharmacies, but romosozumab is a biologic monoclonal antibody that cannot be compounded. There is no generic or compounded version of romosozumab available. All dispensing is of the branded Evenity product manufactured by Amgen/UCB [2].

Cost and Financial Assistance

The wholesale acquisition cost for Evenity is approximately $2,100 per monthly dose, totaling roughly $25,200 for the full 12-month course [13]. Patient out-of-pocket costs vary widely depending on insurance.

Amgen offers the Evenity Co-pay Card for commercially insured patients, which can reduce out-of-pocket costs to as little as $5 per dose. Eligibility requires commercial insurance coverage; patients on government-funded programs (Medicare, Medicaid, Tricare) are not eligible for the co-pay card [14].

For uninsured or underinsured patients, Amgen Assist 360 provides free medication to qualifying individuals. Household income must fall at or below 300% of the federal poverty level. The application requires income documentation and a signed prescription from the treating provider.

The FRAME trial (N=7,180) established that 12 months of romosozumab reduced new vertebral fracture incidence by 73% compared with placebo (0.5% vs. 1.8%, P<0.001), a magnitude of benefit that supports the cost-effectiveness argument when seeking authorization [15].

Timeline: From First Visit to First Injection in Missouri

Patients frequently ask how long the process takes. Here is a realistic timeline.

Week 1. Initial telehealth or in-person consultation. The prescriber orders baseline labs and reviews any existing DXA results.

Week 2. Lab results return. If vitamin D is insufficient, supplementation begins (typically 50 to 000 IU ergocalciferol weekly for 8 weeks). The prescriber submits prior authorization.

Weeks 2 to 4. Prior authorization review period. If approved, the specialty pharmacy receives the prescription.

Week 4 to 5. Specialty pharmacy ships the first dose to the administering clinic. The patient schedules the first injection visit.

Week 5 to 6. First injection administered. The 12-month treatment clock starts.

For patients with adequate vitamin D levels and straightforward insurance, the process can compress to 3 to 4 weeks. For Medicaid patients pursuing exception requests or patients needing vitamin D repletion, expect 8 to 12 weeks.

Transitioning After the 12-Month Romosozumab Course

Romosozumab is FDA-approved for a maximum of 12 monthly doses. The bone-forming effect wanes after one year, and the gains are lost rapidly without sequential antiresorptive therapy [16]. The ARCH trial protocol transitioned patients to alendronate 70 mg weekly after completing romosozumab [4].

The Endocrine Society recommends following romosozumab with either a bisphosphonate (alendronate or zoledronic acid) or denosumab to consolidate the bone density gains [11]. Dr. Felicia Cosman, professor of medicine at Columbia University, has stated: "The anabolic window created by romosozumab must be followed immediately by antiresorptive therapy. Without it, patients lose the majority of gained bone density within 12 to 24 months" [17].

Missouri prescribers should plan the transition therapy before the 12th romosozumab dose. Zoledronic acid (a single annual IV infusion) is a common choice for patients who prefer less frequent dosing. Denosumab (subcutaneous injection every 6 months) is another option, though it carries its own discontinuation risks, including rebound vertebral fractures if stopped abruptly [18].

Monitoring During and After Treatment

During the 12-month romosozumab course, the prescriber should monitor serum calcium at 2 to 4 weeks after initiation and periodically thereafter. Blood pressure and cardiovascular symptoms warrant attention at each monthly injection visit given the boxed warning.

Bone turnover markers (P1NP and CTX) can be checked at baseline, month 3, and month 12 to confirm treatment response. A DXA scan at month 12, just before transitioning to antiresorptive therapy, documents the bone density gained and serves as the new baseline for ongoing monitoring.

Post-treatment DXA scans are typically repeated at 1 to 2 year intervals. The AACE recommends ongoing fracture risk reassessment every 2 to 3 years in patients who remain on antiresorptive therapy after completing an anabolic course [6]. Missouri patients on Medicare are eligible for a DXA scan every 24 months, or more frequently if medically justified.